ODYY · Odyssey Health, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“The operating deficit and negative working capital at April 30, 2026, indicate substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to scale down or perhaps even cease operations. The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty. We are continually adjusting our business plan to reflect our current liquidity expectations. If we are unable to raise additional capital, secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection, we will adjust our business plan. Given our recurring losses, negative cash flow, and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Jun 12, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | $0 | $0 | $0 | $0 | $37.45K | $257.22K | |
| — | — | — | — | — | — | $0 | $0 | $0 | $0 | $20.3K | $228.49K | |
| — | — | — | — | — | — | $0 | $0 | $0 | $0 | $17.15K | $28.73K | |
| — | — | — | — | — | — | — | — | — | — | 45.8% | 11.17% | |
| — | $0 | $55.17K | $201.33K | $1.32M | $1.63M | $20.24K | $23.01M | — | — | — | — | |
| $938.36K | $1.02M | $2.08M | $2.12M | $2.92M | $4.79M | $3.85M | $23.36M | $289K | $167.58K | $90.72K | $184.63K | |
| — | — | $1538 | $3416 | — | — | — | $40.83K | $10K | — | — | — | |
| $0 | — | $1538 | $3416 | $3416 | $2374 | $10.55K | $10.55K | $10.55K | $10.55K | $5138 | $0 | |
| -$938.36K | -$1.02M | -$2.14M | -$5.31M | -$8.11M | -$15.86M | -$3.85M | -$23.58M | -$420.44K | -$167.58K | -$73.57K | -$155.9K | |
| — | — | — | — | — | — | — | — | — | — | -196.43% | -60.61% | |
| -$1.13M | — | -$2.14M | -$5.31M | -$8.1M | -$15.86M | -$3.84M | -$23.57M | -$409.89K | -$157.02K | -$68.43K | -$155.9K | |
| $1.09M | $252.52K | $518.48K | $614.08K | $836.29K | $1.07M | $502.19K | $70.28K | $62.67K | $30.27K | $12.55K | $4800 | |
| -$20.14K | -$10.01K | $9265 | $8677 | — | — | — | — | — | — | — | — | |
| -$27.36K | -$459.42K | -$1.64M | — | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | |
| -$3.57M | -$1.74M | -$842.32K | -$5.92M | -$8.44M | -$16.88M | -$4.35M | -$23.43M | -$483.12K | -$197.84K | -$86.12K | -$160.7K | |
| — | — | — | — | — | — | — | — | — | — | -229.94% | -62.47% | |
| — | -$1.74M | -$905.77K | -$5.92M | — | — | — | — | — | — | — | — | |
| USD/shares | -$0.03 | -$0.02 | -$0.01 | -$0.07 | -$0.09 | -$0.18 | -$0.05 | -$0.34 | $0.00 | $0.00 | $0.00 | $0.00 |
| USD/shares | -$0.03 | -$0.02 | -$0.01 | -$0.07 | -$0.09 | -$0.18 | — | — | — | — | — | — |
| shares | — | 104.71M | 97.06M | 82.68M | 89M | 93.73M | 87.12M | 69.9M | 117.13M | 114.79M | 114.75M | 114.75M |
| shares | — | 104.71M | 97.06M | 82.68M | 89M | 93.73M | — | — | — | — | — | — |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Convertible debt, including current maturities | 2026-04-30 | USD 4,816,493 | 10-Q filed 2026-06-12 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Other notes payable | 2026-04-30 | USD 400,000 | 10-Q filed 2026-06-12 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 32 similar-size Medical Devices companies (of 155 listed).